Year: 2019

TransUnion’s 2020 consumer credit forecast anticipates marginal credit balance growth and broadly stable delinquencies with pockets of stress on certain consumer segmentsAs 2019 draws to a close, overall credit card balances reached a record high of over $100 billion for the first timeTORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) — The Canadian consumer credit market is expected to show marginal balance growth with broadly stable delinquencies over the next year. These predictions were shared as part of the newly released Q3 2019 TransUnion (NYSE: TRU) Industry Insights Report.The report suggests a measured outlook, as Canadians showed signs of some vulnerability in the latest quarter as the consumer credit market continued to adjust to economic uncertainty. TransUnion’s findings revealed the early warning signs of a potentially weakening...

BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) — THL Credit Senior Loan Fund (the “Fund”) (NYSE: TSLF) today reported that THL Credit Advisors LLC, the investment adviser to the Fund (the “Adviser”) entered into a definitive agreement with First Eagle Investment Management, LLC (“First Eagle”), whereby a newly formed subsidiary of First Eagle has agreed, subject to the satisfaction of the closing conditions, to merge with and into the Adviser, with the Adviser as the surviving company (the “Transaction”).  A copy of the joint press release issued by the Adviser and First Eagle related to the Transaction will be available at www.thlcredit.com. Upon consummation of the Transaction, all key personnel of the Adviser who are involved in the management of the Fund are expected to continue to serve...

VANCOUVER, British Columbia, Dec. 09, 2019 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it plans to conduct its first phase 2 clinical trial of its repurposed drug NP-120 (Ifenprodil) for patients with idiopathic pulmonary fibrosis (IPF) and chronic cough.The Company is planning to conduct the phase 2 clinical trial in Australia and will announce the name of the contract research organization (CRO) that will be conducting the trial as well as the principal investigator (PI) shortly.NP-120 (Ifenprodil) outperformed Roche’s Pirfenidone and Boehringer Ingelheim‘s Nintedanib in an IPF animal study and Merck’s MK-7264 (Gefapixant) in a recent acute cough animal study.“We have been...

CALGARY, Alberta, Dec. 09, 2019 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to announce that it has entered into an agreement for the sale of its oil and natural gas interests in the Foothills area of Alberta to an arm’s length private company for total consideration of $1.8 million, subject to customary closing conditions and adjustments (the “Disposition”).  The Disposition has an effective date of November 1, 2019 and is expected to close in the first quarter of 2020. NON-CORE ASSET DISPOSITIONIn the third quarter of 2019, production in the Company’s Foothills area averaged approximately 390 boe/d (64% natural gas), which comprised 5% of Petrus’ total production. The Foothills assets include facility interests and 35,127 net acres of undeveloped land....

MONTREAL, Dec. 09, 2019 (GLOBE NEWSWIRE) — Osisko Metals Incorporated (the “Company” or “Osisko Metals”) (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: 0B51) is pleased to announce new assay results from recently completed exploration drill holes in the East Mill Zone (L37 deposit) at its wholly owned Pine Point Mining Camp (“PPMC”) in the Northwest Territories. Highlights include drill hole L37-19-PP-028 that intersected 9.46% zinc and 0.79% lead over 11.85 metres and drill hole L37-19-PP-035 that intersected 14.83% zinc and 4.45% lead over 4.68 metres. Eight of the nine intersections reported below (Table 1 and L37 Surface Map) were drilled outside the current mineral resource boundary at L37. All intersections are located between 16 to 45 metres vertical depth.Table 1: Drill Highlights.1 True width is expected to be between 95-100% of...

Savosolar PlcCompany Announcement             9 December 2019 at 11.50 a.m. (CET)SAVOSOLAR PLCFor more information:Savosolar PlcManaging Director Jari VarjotiePhone: +358 400 419 734E-mail: jari.varjotie@savosolar.comSavosolar with its highly efficient collectors and large-scale solar thermal systems has taken solar thermal technology to the next level. The company’s collectors are equipped with the patented nano-coated direct flow absorbers, and with this leading technology, Savosolar helps its customers to produce competitive clean energy. Savosolar’s vision is to be the first-choice supplier to high performance solar installations on a global scale. Focus is on large-scale applications like district heating, industrial process heating and real estate systems – market segments with a big potential for rapid growth. The company primarily...

Savosolar OyjYhtiötiedote                       9.12.2019 klo 11.50 (CET)SAVOSOLAR OYJLisätietoja: Toimitusjohtaja Jari VarjotiePuh: +358 400 419 734Sähköposti: jari.varjotie@savosolar.comYhtiön Hyväksytty Neuvonantaja on Augment Partners AB, info@augment.se, puh. +46 8 505 65 172.

Arion Bank will be offering two series of ISK denominated Tier 2 bonds, ARION T2I 30 and ARION T2 30, on 12 December 2019.The bonds constitute Tier 2 capital under Icelandic act on financial undertakings no. 161/2002. The Bank will be offering a fixed rate series, and an inflation linked series. Both series pay interest semi-annually, mature in January 2030 and are callable on and after January 2025. The bonds are expected to be listed on Nasdaq Iceland on 19 December 2019.Arion Bank Capital Markets is the sole bookrunner. For further information please contact Arion Bank’s Capital Markets at verdbrefamidlun@arionbanki.is  

Arion banki verður með útboð á tveimur víkjandi skuldabréfaflokkum, ARION T2I 30 og ARION T2 30, þann 12. desember næstkomandi.Um er að ræða víkjandi skuldabréf sem teljast til eiginfjárþáttar 2, sbr. 84. gr. c. laga nr. 161/2002.  Annars vegar er um að ræða óverðtryggðan flokk og hinsvegar er um að ræða verðtryggðan flokk.  Báðir flokkarnir eru vaxtagreiðslubréf með vaxtagreiðslum tvisvar á ári, með lokagjalddaga í janúar 2030 og eru uppgreiðanlegir frá og með janúar 2025. Stefnt er að töku skuldabréfanna til viðskipta á Nasdaq Iceland þann 19 desember 2019.Verðbréfamiðlun Arion banka hf. annast útgáfuna. Vinsamlegast beinið fyrirspurnum á póstfangið verdbrefamidlun@arionbanki.is